MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Amphastar Pharmaceuticals Accounts Receivables 2011-2026 | AMPH
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Amphastar Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 144 M | 136 M | 115 M | 88.8 M | 78.8 M | 66 M | 45.4 M | 52.2 M | 36 M | 26.8 M | 33.2 M | 22.9 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 144 M | 22.9 M | 70.4 M |
Quarterly Accounts Receivables Amphastar Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 147 M | 133 M | 145 M | 136 M | 140 M | 131 M | - | 115 M | 119 M | - | 101 M | 88.8 M | - | 80.8 M | 73.2 M | 78.8 M | 78.1 M | 67.9 M | 77.9 M | 66 M | 66 M | 66 M | 66 M | 45.4 M | 45.4 M | 45.4 M | 45.4 M | 52.2 M | 52.2 M | 52.2 M | 52.2 M | 36 M | 36 M | 36 M | 36 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | 33.2 M | 33.2 M | 33.2 M | 33.2 M | 22.9 M | 22.9 M | 22.9 M | 22.9 M | 24.6 M | 24.6 M | 24.6 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 147 M | 22.9 M | 62 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Liquidia Corporation
LQDA
|
54.1 M | $ 34.25 | -0.38 % | $ 2.23 B |  USA |
 |
Acorda Therapeutics
ACOR
|
17.3 M | - | -24.86 % | $ 820 K | USA |
 |
I-Mab
IMAB
|
130 M | - | - | $ 866 M |  China |
 |
AbCellera Biologics
ABCL
|
39.4 M | $ 3.58 | -1.38 % | $ 1.07 B |  Canada |
 |
ADMA Biologics
ADMA
|
158 M | $ 15.57 | -5.89 % | $ 3.71 B | USA |
 |
AgeX Therapeutics
AGE
|
57 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aptorum Group Limited
APM
|
62.2 K | $ 0.82 | -0.73 % | $ 4.47 M | China |
 |
Alpine Immune Sciences
ALPN
|
392 K | - | - | $ 2.17 B | USA |
 |
Adverum Biotechnologies
ADVM
|
886 K | - | - | $ 86.2 M | USA |
 |
Anika Therapeutics
ANIK
|
36 M | $ 14.19 | -1.18 % | $ 208 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
222 M | $ 75.6 | -1.22 % | $ 1.46 B | USA |
 |
Apellis Pharmaceuticals
APLS
|
366 M | $ 20.24 | 1.91 % | $ 2.55 B | USA |
 |
Athersys
ATHX
|
739 K | - | 3.77 % | $ 22.4 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
109 K | $ 1.5 | -8.28 % | $ 383 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
9.81 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
224 M | $ 159.87 | -2.57 % | $ 7.95 B | USA |
 |
BridgeBio Pharma
BBIO
|
139 M | $ 65.73 | -1.22 % | $ 12.6 B | USA |
 |
Acasti Pharma
ACST
|
802 K | - | 4.01 % | $ 150 M | Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
312 K | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
56.9 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
865 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
205 K | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
18.5 M | - | -7.31 % | $ 87 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
908 M | $ 60.54 | 0.18 % | $ 11.6 B | USA |
 |
CymaBay Therapeutics
CBAY
|
277 K | - | - | $ 3.45 B | USA |
 |
Codexis
CDXS
|
25 M | $ 1.25 | 16.2 % | $ 91.8 M | USA |